ENGN
enGene Therapeutics Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
enGene Therapeutics Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No changes.
No changes.
No thesis.
Largest filed tie
0
filed ties
—
Annual filing, covered
10-K parsed · Dec 22 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Dec 22 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
enGene Therapeutics Inc.
1.72
+0.10 · +6.17%
post 1.72 0.00%
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for enGene Therapeutics Inc..
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for enGene Therapeutics Inc..
| Manager | Value | % base | |
|---|---|---|---|
| BML | $11.5M | 17.10% | new |
| Siren | $10.8M | 16.04% | new |
| Perceptive | $8.3M | 12.36% | new |
| Ameriprise Financial | $4.6M | 6.86% | new |
| Nextech Invest | $4.0M | 5.96% | new |
| Manager | Value | % base | |
|---|---|---|---|
| BML | $11.5M | 17.10% | new |
| Siren | $10.8M | 16.04% | new |
| Perceptive | $8.3M | 12.36% | new |
| Ameriprise Financial | $4.6M | 6.86% | new |
| Nextech Invest | $4.0M | 5.96% | new |
Tall tick = annual report · Source: EDGAR
Expected move
No implied move.